SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans
Scienture Holdings, Inc. (SCNX)
Company Research
Source: GlobeNewswire
Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL has been added to the formularies of key national payors, expanding access through both multiple commercial coverage and Medicare supplement plans. This inclusion extends availability to over 100 million covered lives across the United States. Arbli™ is the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium, designed to provide a safe, consistent, and convenient therapeutic option for patients requiring an alternative to solid dosage forms. According to
Show less
Read more
Impact Snapshot
Event Time:
SCNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SCNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SCNX alerts
High impacting Scienture Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
SCNX
News
- Scienture (NASDAQ:SCNX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025 [Yahoo! Finance]Yahoo! Finance
- SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025GlobeNewswire
- Scienture (NASDAQ:SCNX) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
SCNX
Sec Filings
- 11/18/25 - Form 8-K
- 11/14/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- SCNX's page on the SEC website